VivoSim Labs Inc. Stock Analysis VIVS

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 13 full-time employees. The company went IPO on 2013-08-02. The firm offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The firm offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. The company uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The firm also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.